tirzepatide cardiovascular risk In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT Possible mechanisms of Tirzepatide's cardiovascular

You're asking clinically-relevant questions, and then yeah

These factors create substantial disparities in who can obtain and maintain treatment, despite clinical eligibility

[DOI] [PMC free article] [PubMed] [Google Scholar] 18.Meldrum DR, Morris MA, Gambone JC

doi: 10.3389/ffunb.2025.1742455 Received 09 November 2025 Revised 01 December 2025 Accepted 02 December 2025 Published 18 December 2025 Volume 6 - 2025 Edited by Samantha Chandranath Karunarathna, Qujing Normal University, China Reviewed by Akruti Singh, University of Petroleum and Energy Studies, India Updates Copyright 2025 Wang, Wang and Meade

SURMOUNT-1: Faza 2 badania, w ktrym uczestniczyo 478 pacjentw z nadwag, bez cukrzycy